Nycomed to market Roche's osteoporosis treatment Bonviva in key Asia-Pacific markets
Nycomed has completed the transfer of marketing authorization approvals in a number of key Asia-Pacific markets for osteoporosis treatment Bonviva (Ibandronate). The licensing agreement with Roche marks a further strengthening of Nycomed's bone health franchise in the region.
The licensing and supply agreement includes China, Hong Kong, Malaysia, Australia, New Zealand, Philippines, Singapore, Taiwan and Vietnam and a future option to commercialize Bonviva in additional Asia-Pacific territories.
Under the terms of the deal, Nycomed will become marketing authorisation holder in all the licensed territories. Bonviva is a bisphosphonate used in the
treatment of osteoporosis in postmenopausal women. Financial details of the agreement were not disclosed.
Nycomed has one of the highest proportions of sales from emerging markets among major pharmaceutical companies. The company recently opened offices in China, South Korea, Indonesia, Malaysia and the Philippines, rapidly increasing its capabilities through the repatriation of its own core brands and the licensing of innovative products from other companies.
In November 2010 Nycomed made a major commitment to the Chinese market through the acquisition of a majority stake in Guangdong Techpool Bio-Pharma, which specializes in protein-based therapies.
Commenting on today's announcement Guido Oelkers, Executive Vice President, Commercial Operations, said: "The in-licensing of Bonviva from Roche is another important step towards Nycomed's expansion in the Asia-Pacific region and demonstrates our growing attraction as a marketing partner for leading companies and brands in these dynamic countries. Bonviva is a high quality product which plays an important role in combating the impact of osteoporosis in post menopausal women."